Skip to main content
. 2023 Sep 18;3(10):1201–1209. doi: 10.1038/s43587-023-00478-y

Extended Data Fig. 6. Differential expression analyses of patients with LBD compared to controls in the BioFINDER-1 cohort with CSF samples.

Extended Data Fig. 6

Results comparing all clinical unimpaired individuals or controls (CTR) to Lewy body disease (LBD) patients. The upper horizontal indicates proteins that survived FDR corrections. The strongest top hit corresponded to DOPA decarboxylase (DDC, also known as aromatic L-amino acid decarboxylase).